UC Davis

UC Davis Previously Published Works

Title

From MDS/AML to iPSC and back again.

Permalink

<https://escholarship.org/uc/item/4hn2v49s>

Journal

Science translational medicine, 9(380)

ISSN

1946-6234

Author

Jonas, Brian A

Publication Date

2017-03-01

DOI

10.1126/scitranslmed.aam9861

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

Advertisement

INNOVATING FOR A
SMARTER WORLD

gmV[®]
INNOVATING SOLUTIONS

Institution: UNIV OF CALIFORNIA - DAVIS

Log in

My account

Contact Us

Become a member

Renew my subscription

Sign up for newsletters

EDITORS' CHOICE | CANCER

From MDS/AML to iPSC and back again

Brian A. Jonas

Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. Email: bajonas@ucdavis.edu

+ See all authors and affiliations

Science Translational Medicine 08 Mar 2017:
Vol. 9, Issue 380,
DOI: 10.1126/scitranslmed.aam9861

- Article
- Info & Metrics
- eLetters

Abstract

iPSC lines derived from MDS and AML patient samples can map clonal evolution, disease progression and regression, and identify disease stage-specific medication effects.

Acute myeloid leukemia (AML) is an aggressive clonal blood and bone marrow cancer that can arise de novo or from preexisting hematologic diseases, such as myelodysplastic syndromes (MDS). It is now well established that AML evolves from hematopoietic stem and progenitor cells (HSPCs) through the step-wise accumulation of multiple genetic changes. However, functional studies of the evolution from MDS to AML are limited by the relative inability of primary MDS cells to grow and transplant. Patient-derived induced pluripotent stem cells (iPSCs) are being evaluated as potential platforms for studying cancer progression,

genetics, and treatment, including a recent report by Kotini *et al.* investigating iPSCs derived from patients with myeloid diseases.

Using primary MDS and AML patient samples, Kotini *et al.* developed a reprogrammed panel of patient-derived iPSC lines spanning the entire myeloid disease spectrum, including normal, preleukemic, MDS, and AML stages. Notably, the reprogramming potential of each patient sample was mutation-specific. The investigators selected iPSC lines representative of different disease stages and used a hematopoietic differentiation protocol to characterize the phenotype of each disease stage-specific line. Hematopoietic progenitor cells (HPCs) derived from these iPSC lines demonstrated graded disease stage-specific changes in dysplasia, progenitor loss, differentiation block, cell growth rate, gene expression, and engraftment in NOD/SCID/IL-2 γ^{null} mice that mapped the phenotypic transformation from normal HSPCs to fulminant and serially transplantable leukemia. Next, the investigators used genome-editing methods to model clonal evolution and showed that iPSC lines from distinct disease stages could be transitioned forward or backward through the introduction or correction of specific mutations. Last, iPSC-derived HPCs showed disease stage-specific responses to drug treatment.

This study used cell reprogramming and genetics to develop a panel of patient-derived, disease stage-specific iPSC lines that provides a phenotypic roadmap of myeloid disease progression and can be custom tailored through genome editing approaches. The small number of primary patient samples and inability of some cells with specific mutations to reprogram are limitations; overall, however, stage-specific iPSC lines represent a powerful new tool for functional studies of myeloid diseases, demonstrating proof of principle that treatment effects can be studied in these models with potentially broader cancer applicability.

Highlighted Article

A. G. Kotini, C. J. Chang, A. Chow, H. Yuan, T. C. Ho, T. Wang, S. Vora, A. Solovyov, C. Husser, M. Olszewska, J. Teruya-Feldstein, D. Perumal, V. M. Klimek, A. Spyridonidis, R. K. Rampal, L. Silverman, E. P. Reddy, E. Papaemmanuil, S. Parekh, B. D. Greenbaum, C. S. Leslie, M. G. Kharas, E. P. Papapetrou, Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. *Cell Stem Cell* **20**, 315–328.e7 (2017). [▶ UC-eLinks](#) [UC-eLinks](#) [Google Scholar](#)

Copyright © 2017, American Association for the Advancement of Science

View Abstract

Science Translational Medicine

Vol 9, Issue 380

08 March 2017

[Table of Contents](#)

ARTICLE TOOLS

- Email
- Save to my folders
- Alerts
- Request Permissions
- Citation tools
- Share

Advertisement

SIMILAR ARTICLES IN:

- [Google Scholar](#)

Advertisement

EXCLUSIVE PROMOTION
FOR ACADEMIC LEADERS

Prep Your
Grad Students for
Career Success

Career Development Center

NAVIGATE THIS ARTICLE

- [Article](#)
 - [Abstract](#)
 - [Highlighted Article](#)
- [Info & Metrics](#)
- [eLetters](#)

Science

3 March 2017

Vol 355, Issue 6328

FEATURE

Into the Twilight Zone

POLITICAL SCIENCE

The need for a translational science of democracy

EXHIBITION

Deep exposures

SCI COMMUN

News at a glance

PLANT PATHOGENS

Durable resistance to rice blast

WORKING LIFE

Sailing through uncertainty

Table of Contents

Subscribe Today

Receive a year subscription to *Science* plus access to exclusive AAAS member resources, opportunities, and benefits.

Subscribe Today

Get Our Newsletters

Enter your email address below to receive email announcements from Science. We will also send you a newsletter digest with the latest published articles. [See full list](#)

- ☐ Science Translational Medicine TOC
- ☐ *Science* Table of Contents
- ☐ *Science* Daily News
- ☐ *Science* News This Week
- ☐ *Science* Editor's Choice
- ☐ First Release Notification

Sign up today

About us

- About journals
- Leadership
- Team members
- Work at AAAS

Advertise

- Advertising kits
- Custom publishing

For subscribers

- Site license info
- For members

International

- Chinese

Japanese

Help

Access & subscriptions

Reprints & permissions

Contact us

Accessibility

Stay Connected

© 2017 American Association for the Advancement of Science. All rights Reserved. AAAS is a partner of HINARI, AGORA OARE, PatientInform, CHORUS, CLOCKSS, CrossRef and COUNTER. *Science Translational Medicine* ISSN 1946-6242.

Terms of Service

Privacy Policy

Contact Us